Altimmune, Inc. (ALT)
3.155
-0.04
(-1.41%)
USD |
NASDAQ |
Aug 26, 16:00
3.155
0.00 (0.00%)
After-Hours: 17:24
Altimmune Price to Book Value : 1.294 for Aug. 26, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 1.312 |
| August 24, 2026 | 1.275 |
| August 21, 2026 | 1.275 |
| August 20, 2026 | 1.210 |
| August 19, 2026 | 1.280 |
| August 18, 2026 | 1.218 |
| August 17, 2026 | 1.230 |
| August 14, 2026 | 1.206 |
| August 13, 2026 | 1.181 |
| August 12, 2026 | 1.202 |
| August 11, 2026 | 1.230 |
| August 10, 2026 | 1.251 |
| August 07, 2026 | 1.263 |
| August 06, 2026 | 1.234 |
| August 05, 2026 | 1.243 |
| August 04, 2026 | 1.259 |
| August 03, 2026 | 1.230 |
| July 31, 2026 | 1.165 |
| July 30, 2026 | 1.222 |
| July 29, 2026 | 1.198 |
| July 28, 2026 | 1.226 |
| July 27, 2026 | 1.214 |
| July 24, 2026 | 1.136 |
| July 23, 2026 | 1.165 |
| July 22, 2026 | 1.152 |
| Date | Value |
|---|---|
| July 21, 2026 | 1.156 |
| July 20, 2026 | 1.152 |
| July 17, 2026 | 1.177 |
| July 16, 2026 | 1.169 |
| July 15, 2026 | 1.222 |
| July 14, 2026 | 1.202 |
| July 13, 2026 | 1.226 |
| July 10, 2026 | 1.251 |
| July 09, 2026 | 1.280 |
| July 08, 2026 | 1.275 |
| July 07, 2026 | 1.238 |
| July 06, 2026 | 1.263 |
| July 02, 2026 | 1.296 |
| July 01, 2026 | 1.292 |
| June 30, 2026 | 1.247 |
| June 29, 2026 | 1.348 |
| June 26, 2026 | 1.293 |
| June 25, 2026 | 1.316 |
| June 24, 2026 | 1.353 |
| June 23, 2026 | 1.334 |
| June 22, 2026 | 1.344 |
| June 18, 2026 | 1.238 |
| June 17, 2026 | 1.211 |
| June 16, 2026 | 1.201 |
| June 15, 2026 | 1.211 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 20.36 |
| Protalix Biotherapeutics, Inc. | 2.793 |
| Taysha Gene Therapies, Inc. | 5.053 |
| Humacyte, Inc. | 6.089 |
| Liquidia Corp. | 32.58 |
Price to Book Value Related Metrics
| PS Ratio | 12720.17 |
| Price | 3.155 |
| Earnings Yield | -25.00% |
| Market Cap | 613.57M |